US Patent Issued to Janssen Biotech on March 25 for "Method of treating inflammatory bowel disease with a combination therapy of antibodies to IL-23 and TNF alpha" (Pennsylvania Inventors)

ALEXANDRIA, Va., March 26 -- United States Patent no. 12,258,393, issued on March 25, was assigned to Janssen Biotech Inc. (Horsham, Pa.).

"Method of treating inflammatory bowel disease with a combination therapy of antibodies to IL-23 and TNF alpha" was invented by Matthew Germinaro (Philadelphia), Christopher O'Brien (Lafayette Hill, Pa.), Jacqueline Perrigoue (Oreland, Pa.) and Marion Vetter (Spring House, Pa.).

According to the abstract* released by the U.S. Patent & Trademark Office: "A method of treating inflammatory bowel disorders, such as ulcerative colitis, comprises administering an IL-23 inhibitor, such as an anti-IL-23p19 antibody (e.g., guselkumab) and a TNF-Alpha inhibitor, such as an anti-TNF-Alpha antibody (e.g., golimuma...